Guillermina Ferro-Flores, Blanca Ocampo-García, Pedro Cruz-Nova, Myrna Luna-Gutiérrez, Gerardo Bravo-Villegas, Erika Azorín-Vega, Nallely Jiménez-Mancilla, Emiliano Michel-Sánchez, Osvaldo García-Pérez, Nancy Lara-Almazán, Clara Santos-Cuevas
Recent cancer therapies have focused on reducing immune suppression in the tumor microenvironment to prevent cancer progression and metastasis. PD-1 is a checkpoint protein that stops the immune response and is expressed on immune T cells. Cancer cells express a PD-1 ligand (PD-L1) to bind to the T-cell surface and activate immunosuppressive pathways. This study aimed to design, synthesize, and evaluate a 99m Tc-labeled PD-L1-targeting cyclic peptide inhibitor (99m Tc-iPD-L1) as a novel SPECT radiopharmaceutical for PD-L1 expression imaging...
November 23, 2023: Pharmaceutics